Biogen Inc (BIIB)
201.99
+8.81
(+4.56%)
USD |
NASDAQ |
Apr 24, 16:00
202.70
+0.71
(+0.35%)
Pre-Market: 08:13
Biogen Enterprise Value: 35.25B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 35.25B |
| April 23, 2024 | 33.97B |
| April 22, 2024 | 34.10B |
| April 19, 2024 | 34.14B |
| April 18, 2024 | 33.58B |
| April 17, 2024 | 33.82B |
| April 16, 2024 | 34.26B |
| April 15, 2024 | 34.50B |
| April 12, 2024 | 34.70B |
| April 11, 2024 | 35.50B |
| April 10, 2024 | 35.19B |
| April 09, 2024 | 35.91B |
| April 08, 2024 | 35.68B |
| April 05, 2024 | 35.52B |
| April 04, 2024 | 35.73B |
| April 03, 2024 | 35.89B |
| April 02, 2024 | 36.07B |
| April 01, 2024 | 37.12B |
| March 28, 2024 | 37.23B |
| March 27, 2024 | 37.34B |
| March 26, 2024 | 36.71B |
| March 25, 2024 | 37.39B |
| March 22, 2024 | 37.59B |
| March 21, 2024 | 37.98B |
| March 20, 2024 | 37.60B |
| Date | Value |
|---|---|
| March 19, 2024 | 37.67B |
| March 18, 2024 | 37.78B |
| March 15, 2024 | 37.77B |
| March 14, 2024 | 37.81B |
| March 13, 2024 | 38.82B |
| March 12, 2024 | 38.94B |
| March 11, 2024 | 39.33B |
| March 08, 2024 | 38.34B |
| March 07, 2024 | 37.77B |
| March 06, 2024 | 37.51B |
| March 05, 2024 | 37.47B |
| March 04, 2024 | 38.02B |
| March 01, 2024 | 38.01B |
| February 29, 2024 | 37.43B |
| February 28, 2024 | 38.12B |
| February 27, 2024 | 38.44B |
| February 26, 2024 | 38.41B |
| February 23, 2024 | 38.35B |
| February 22, 2024 | 38.23B |
| February 21, 2024 | 38.03B |
| February 20, 2024 | 37.75B |
| February 16, 2024 | 37.73B |
| February 15, 2024 | 38.35B |
| February 14, 2024 | 37.98B |
| February 13, 2024 | 38.83B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
30.72B
Minimum
Sep 06 2022
67.15B
Maximum
Jun 10 2021
43.97B
Average
43.75B
Median
Oct 17 2023
Enterprise Value Benchmarks
| Eli Lilly and Co | 718.54B |
| Bristol-Myers Squibb Co | 126.35B |
| Gilead Sciences Inc | 101.21B |
| AbbVie Inc | 343.02B |
| Regeneron Pharmaceuticals Inc | 90.64B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 249.70M |
| Revenue (Quarterly) | 2.386B |
| Total Expenses (Quarterly) | 1.929B |
| EPS Diluted (Quarterly) | 1.71 |
| Gross Profit Margin (Quarterly) | 74.09% |
| Profit Margin (Quarterly) | 10.46% |
| Earnings Yield | 3.95% |
| Operating Earnings Yield | 6.24% |
| Normalized Earnings Yield | 5.509 |